Eevia Health reopens ingredient factory after investments

Eevia Health Oy, a Finnish producer of health ingredients made from organically certified plant extracts, has upgraded its green-chemistry manufacturing plant in Finland to meet strong demand from customers

During the first four months of 2020, Eevia Health invested in new equipment, machines and technology to improve functionality, productivity and throughput of the special-purpose ingredient factory.

The equipment-upgrade amount to an investment of approximately €1 million and is 100% equity financed by Eevia Health owners. It includes significant improvement in functionality, directed at maintaining high quality in the extraction process of complex compounds from natural plant material.

Located near the harvest areas of its raw materials, Eevia Health offers the shortest value chain in the industry, a strong focus on sustainability and traceability and products with an environmentally friendly carbon footprint.

“We are very pleased to have completed this factory upgrade. It puts us as a competitive company for high quality, branded ingredients in a €500 billion global nutraceutical ingredients market. The investments will especially benefit our manufacturing of polyphenolic extracts from arctic bilberries and lingonberries, as well as elderberries.

"Some of the improvements are radical. For instance, earlier, the residence time (the time the extracted liquid has to be in the process step) for extraction liquids in one process step was 4 hours, whiles now this step only takes a few seconds. This greatly benefits quality," says CEO and founder Stein Ulve from Eevia Health Oy.

Eevia Health Oy will celebrate the reopening of its modern green chemistry production facility in Kauhajoki, with a formal opening ceremony as a live-streamed webinar at the end of June.

Eevia Health Oy, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant material from the pristine Finnish forests above the Arctic Circle. The focus is on products that protect human health prophylactically, meaning they work to reduce the risk of developing a disease.

In its portfolio, Eevia Health has immune-modulating products that have effects on Th1-type cytokines, such as IFN- γ and TNF-α cell signalling molecules, which are very important in the immune response to pathogens (virus, etc.).

Like this story? Subscribe to Nutraceutical Business Review magazine for incisive analysis, the latest news and expert-written articles from the functional food and drink industries. For more information click here.

Similarly, Eevia Health is developing a new product that prevents protein accumulation in the RPE-cells in the retina, which may reduce the risk of developing the eye disease AMD (Age-Related Macular Degeneration).

Eevia Health is a small, but fast-growing Finnish manufacturer of 100% organically certified plant extracts. All raw materials, such as lingonberry, bilberry, Chaga mushroom and pine bark, are grown in the wild and hand-picked in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland, located close to the raw material forest source in Finnish Lapland. All the ingredients are organically certified. The short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency.

The green chemistry extraction and enrichment technologies Eevia Health Oy operate, allow for safe and effective ingredients of high quality, for dietary supplements and other applications. Eevia Health value proposition offers safe and effective products made with responsible practices, transparency and authenticity.

The ingredients, such as high concentrate bilberry anthocyanin extracts (36%) and pine bark extracts, are sold globally as ingredients to dietary supplement and food applications.

Companies